Biofil Chemicals & Pharmaceuticals Ltd. (IN:BIOFILCHEM)
:BIOFILCHEM
Top Page
Biofil Chemicals & Pharmaceuticals Ltd.
(BIOFILCHEM)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹33.00
▼(-1.76% Downside)
Action:ReiteratedDate:04/08/26
The score is held back primarily by weak cash flow quality and an expensive valuation (very high P/E with no dividend yield provided). A comparatively healthier balance sheet provides some support, while technical indicators are neutral-to-weak with negative MACD and a longer-term trend that remains under pressure.
Positive Factors
Balance Sheet Strength
Manageable leverage and a strong equity ratio provide structural financial resilience. Over a 2-6 month horizon this supports the firm's ability to absorb industry shocks, access funding on better terms, and prioritize strategic spending without immediate refinancing pressure.
Negative Factors
Revenue Decline
A steep revenue decline materially reduces scale and weakens the firm's competitive position. Over several months this compresses operating leverage, constrains margins, and limits funds available for R&D, marketing, or capacity investments that support long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Manageable leverage and a strong equity ratio provide structural financial resilience. Over a 2-6 month horizon this supports the firm's ability to absorb industry shocks, access funding on better terms, and prioritize strategic spending without immediate refinancing pressure.
Read all positive factors
Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹543.54M
Dividend YieldN/A
Average Volume (3M)6.87K
Price to Earnings (P/E)172.4
Beta (1Y)1.28
Revenue Growth36.76%
EPS Growth433.63%
CountryIN
Employees26
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding16,273,800
10 Day Avg. Volume7,559
30 Day Avg. Volume6,869
Financial Highlights & Ratios
PEG Ratio-5.50
Price to Book (P/B)3.72
Price to Sales (P/S)2.09
P/FCF Ratio-34.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biofil Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine c...
How the Company Makes Money
null...
Biofil Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
75
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 425.20M | 334.02M | 400.35M | 300.35M | 223.82M | 357.50M |
| Gross Profit | 19.32M | 20.91M | 25.28M | 25.63M | 28.66M | 33.23M |
| EBITDA | 36.91M | 11.53M | 13.06M | 12.65M | 14.83M | 23.99M |
| Net Income | 28.59M | 5.58M | 7.09M | 5.60M | 6.98M | 12.41M |
Balance Sheet | ||||||
| Total Assets | 553.64M | 509.60M | 470.83M | 314.06M | 187.32M | 332.38M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 2.55M | 22.84M | 377.00K | 1.45M | 4.41M |
| Total Debt | 200.00K | 4.71M | 4.39M | 5.22M | 4.65M | 4.30M |
| Total Liabilities | 340.59M | 321.79M | 288.80M | 141.04M | 18.95M | 171.09M |
| Stockholders Equity | 213.04M | 187.82M | 182.03M | 173.01M | 168.38M | 161.29M |
Cash Flow | ||||||
| Free Cash Flow | -36.36M | -20.24M | 23.71M | -1.22M | -2.90M | 5.44M |
| Operating Cash Flow | -35.65M | -19.24M | 23.94M | -1.12M | -2.20M | 11.11M |
| Investing Cash Flow | 41.30M | -1.00M | -229.00K | -106.00K | -699.00K | -961.00K |
| Financing Cash Flow | -4.61M | -45.00K | -1.25M | 151.00K | -58.00K | -8.30M |
Biofil Chemicals & Pharmaceuticals Ltd. Technical Analysis
Positive
33.59
Price Trends
32.33
Positive
33.64
Negative
38.55
Negative
Market Momentum
-0.52
Negative
59.53
Neutral
82.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOFILCHEM, the sentiment is Positive. The current price of 33.59 is above the 20-day moving average (MA) of 29.74, above the 50-day MA of 32.33, and below the 200-day MA of 38.55, indicating a neutral trend. The MACD of -0.52 indicates Negative momentum. The RSI at 59.53 is Neutral, neither overbought nor oversold. The STOCH value of 82.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BIOFILCHEM.
Biofil Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ₹1.20B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
56 Neutral | ₹543.54M | 172.45 | ― | ― | 36.76% | 433.63% | |
52 Neutral | ₹662.45M | 21.33 | ― | ― | 18.35% | -154.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹493.52M | -1.11 | ― | ― | -24.55% | -310.57% | |
45 Neutral | ₹376.26M | -4.63 | ― | ― | -20.40% | -59.20% |
* Healthcare Sector Average
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
33.40
-10.13
-23.27%
IN:BALPHARMA
Bal Pharma Limited
75.11
-29.51
-28.21%
IN:LASA
Lasa Supergenerics Ltd.
7.51
-9.81
-56.64%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
31.18
-45.24
-59.20%
IN:VAISHALI
Vaishali Pharma Ltd.
6.18
-6.03
-49.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.